Business
B USINESS BUSINESS Overview We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs for virology and immunology indications.
ENANTA PHARMACEUTICALS INC: Revenue declined 3.4% to $65.32M from $67.64M. Net loss narrowed to $81.89M from $116M. Free cash flow outflow narrowed to $32.17M from $96.71M. Operating margin expanded 4927 bps to -130.65%. ENANTA PHARMACEUTICALS INC's annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context; the earnings-quality screen is grey.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 3.4% to $65.32M from $67.64MWatch
- Profitability — Net loss narrowed to $81.89M from $116MOK
- Cash flow — Free cash flow outflow narrowed to $32.17M from $96.71MOK
- Margins — Operating margin expanded 4927 bps to -130.65%OK
- Accounting — Distress-range screen needs contextWatch
- Insiders — 0 purchases and 9 salesWatch
Where the revenue comes from
Fiscal 2025, as ENANTA PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Royalty$65.3M
Latest filings
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-06-23
- 8-K · Company announcement2026-06-18
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ENANTA PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.